Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 107

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 107
---
 The following table sets forth our consolidated cash, cash equivalents and short-term investments and capitalization, as of September 30, 2024. Such information is set forth on the following basis:

| ● | on an actual basis;                                                                                                                |
| ● | on a pro forma basis to                                                                                                            
 reflect the issuance of (i) 79,040 shares issued to our officers as 2024 bonuses, (ii) 2,898,551 shares issued for the exercise of 
 2,898,551 pre-funded warrants after September 30, 2024 but prior to the date of this prospectus supplement, (iii) 1,021,549 shares 
 of common stock issued in the January 2025 Offering based on the offering price of $1.021 per share of common stock net of certain 
 offering expenses, and (iv) 1,503,500 shares of common stock issued in the February 2025 Offering based on the offering price of   
 $0.715 per share of common stock net of certain offering expenses; and                                                             |

| ● | on a pro forma as adjusted                                                                                                                  
 basis to reflect our receipt of the gross proceeds from the full exercise of the Common Warrants and the Placement Agent Warrants resulting 
 in the issuance of 3,735,977 shares of common stock at a weighted average exercise price of $0.7122 per share.                              |

You should read the following table in conjunction with “ Use of Proceeds,” “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included in this prospectus. The following table sets forth our cash, cash equivalents and short-term investments and capitalization as of September 30, 2024 (in thousands):

|                                                                                                                                                                                                                                                                          |     | Actual |             |   |     | Pro Forma(1) |             |   |     | Pro Forma      
 as adjusted(1) |             |   |
|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|------------:|:--|:----|:-------------|------------:|:--|:----|:---------------|------------:|:--|
| Cash, cash equivalents, and short-term investments                                                                                                                                                                                                                       |     | $      |   5,012,185 |   |     | $            |   6,853,057 |   |     |                |   9,513,923 |   |
| Total long-term liabilities                                                                                                                                                                                                                                              |